Bausch Health Companies (BHCN) Stock Price & Analysis
BHCN Stock Chart & Stats
- Day’s Range
- MXN 123.00 - MXN 123.00
- 52-Week Range
- MXN 83.00 - MXN 136.35
- Previous Close
- MXN 123.00
- Volume
- 0
- Average Volume (3M)
- 7
- Market Cap
- MXN 57.70B
- Enterprise Value
- MXN 30.44B
- Total Cash (Recent Filing)
- MXN 2.47B
- Total Debt (Recent Filing)
- MXN 20.58B
- Price to Earnings (P/E)
- ―
- Beta
- -0.24
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- 25.36
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Sustained Diversified Growth
Broad-based growth across therapeutic and geographic segments reduces reliance on any single product or market. The company’s 14-quarter record of revenue and adjusted EBITDA growth indicates durable commercial execution and supports continued reinvestment across its portfolio.
Strong Cash Generation
Strong operating and free cash flow provides internal funding for debt reduction, product development and commercial investment. Improving free cash flow conversion strengthens resilience and gives management more flexibility to allocate capital without relying solely on external financing.
Operating Leverage And Guidance
Higher earnings and cash-flow guidance, together with reported margin expansion, suggests operating leverage is becoming embedded in the business. If execution continues, this can support stronger deleveraging capacity and improve the durability of cash earnings over the next several quarters.
Bears Say
Highly Levered Balance Sheet
Very high debt combined with negative equity leaves Bausch Health with a thin capital buffer and reduced financial flexibility. The structure increases exposure to refinancing and interest burdens, making the company more sensitive to any sustained deterioration in operating performance.
Xifaxan Pricing Pressure
Xifaxan remains an important growth contributor, but the anticipated CMS and IRA-related pricing impact creates a durable headwind to revenue and profitability. This pressure could reduce cash available for deleveraging and make future growth more dependent on other products and segments.
Persistent Bottom-line Losses
Despite solid operating margins and cash generation, recurring net losses show that below-the-line costs or charges continue to absorb operating performance. This weakens reported earnings quality, limits balance-sheet repair through retained profits, and increases dependence on sustained operational improvement.
BHCN FAQ
What was Bausch Health Companies’s price range in the past 12 months?
What is Bausch Health Companies’s market cap?
When is Bausch Health Companies’s upcoming earnings report date?
How were Bausch Health Companies’s earnings last quarter?
Is Bausch Health Companies overvalued?
Does Bausch Health Companies pay dividends?
What is Bausch Health Companies’s EPS estimate?
How many shares outstanding does Bausch Health Companies have?
What happened to Bausch Health Companies’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bausch Health Companies?
What is the TipRanks Smart Score and how is it calculated?
Bausch Health Companies Stock Smart Score
Company Description
Bausch Health Companies
Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Thomas J. Appio
- Employees
- 20,300
- Website
- www.bauschhealth.com
- Address
- 2150 St. ElzEar Boulevard West, Laval, QC, H7L 4A8, CA
Bausch Health Companies (BHCN) Earnings & Revenues
BHCN Company Deck
BHCN Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Highlights significantly outweighed the lowlights, supported by broad-based revenue and profit growth, record adjusted EBITDA for Bausch Health excluding Bausch + Lomb, substantial cash generation and debt reduction, another increase in full-year guidance, and continued pipeline and portfolio development. The principal challenges were expected Q4 and 2027 Xifaxan pricing and inventory effects, Solta's quarterly organic decline and market competition, and unresolved litigation timing.
View all MX:BHCN earnings summariesBHCN Net sales Breakdown
- 47.34% Bausch + Lomb
- 25.69% Salix
- 12.23% International
- 10.77% Diversified Products
- 3.96% Solta Medical
BHCN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 0 | 5 |
| Technical Analysis | 3 | 0 | 5 |
| Moving Averages | 12 | 0 | 0 |
